SFI
NBIX icon

Siemens Fonds Invest’s Neurocrine Biosciences NBIX Stock Holding History

Siemens Fonds Invest’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$235K Hold
1,392
– – 0.01% 454
2026
Q1 		$183K Hold
1,392
– – 0.01% 480
2025
Q4 		$196K Hold
1,392
– – 0.01% 476
2025
Q3 		$195K Sell
1,392
-16
-1% -$2.17K 0.01% 471
2025
Q2 		$177K Buy
1,408
+305
+28% +$35K 0.01% 477
2025
Q1 		$122K Buy
+1,103
New +$140K 0.01% 515

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Siemens Fonds Invest's NBIX Position: Q2 2026 in Review

Siemens Fonds Invest held its Neurocrine Biosciences (NBIX) position steady in Q2 2026 at 1,392 shares worth $235K. The position accounts for 0.01% of the portfolio, ranked #454.

Siemens Fonds Invest first reported a position in NBIX in Q1 2025 and has held it in 6 quarters since. 781 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Siemens Fonds Invest held 1,392 shares of Neurocrine Biosciences worth $235K as of Q2 2026.
  • Siemens Fonds Invest left its Neurocrine Biosciences share count unchanged in Q2 2026.
  • Neurocrine Biosciences made up 0.01% of Siemens Fonds Invest's portfolio in Q2 2026, its #454 holding.
  • Siemens Fonds Invest first reported a position in Neurocrine Biosciences in Q1 2025 and has held it in 6 quarters since.
  • 781 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Siemens Fonds Invest's 13F filing for Q2 2026, filed 14 Aug 2026.